产品
编 号:F001162
分子式:C24H32ClN5O2
分子量:458
产品类型
结构图
CAS No: 1001264-89-6
联系客服
产品详情
生物活性:
Ipatasertib (GDC-0068) is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC50 values of 5, 18, 8 nM for Akt1/2/3, respectively. Ipatasertib synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. Ipatasertib also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models.
体内研究:
Ipatasertib (30 mg/kg; p.o.; single daily for 15 consecutive days) 在野生型和 PUMA?/? 型 HCT116 异种移植小鼠模型中显示出 PUMA依赖性抗肿瘤活性。Animal Model:HCT116 WT and PUMA?/? cells xenograft nude mice model.
Dosage:30 mg/kg
Administration:Oral gavage; single daily for 15 consecutive days.
Result:Inhibited growth of tumors in a PUMA-dependent manner.
体外研究:
Ipatasertib (10 μM; 12, 24 h) 在细胞实验中,通过非 p53 依赖性的 PUMA 激活抑制结肠癌细胞增殖。Ipatasertib (1, 5, 10, 20 μM; 24 h/10 μM; 3, 6, 12, 24 h) 在 HCT116 细胞中,以时间和浓度依赖的方式上调 PUMA 的表达。Ipatasertib 在野生型、p53?/? 型, 以及 DLD1 (p53 突变) 型 HCT116 细胞中增加 PUMA 的 mRNA 水平。Ipatasertib (10 μM; 24 h) 通过 PUMA/Bax 途径诱导 HCT116 细胞凋亡。